From: BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance
CML | stage | IC50 imatinib (nM) | IC50 nilotinib (nM) | IC50 dasatinib (nM) | BCR-ABL1 mu/wt | BCR-ABL1 breakpoint | Ikaros Ik6 | BCR-ABL1 mRNA expression level |
---|---|---|---|---|---|---|---|---|
BV-173 | B BC | 100 | < 10 | n.d. | n.d. | b2-a2 | yes | 1.6 |
CML-T1 | T BC | 200 | 20 | n.d. | n.d. | b2-a2 | no | 0.5 |
EM-2 | M BC | 80 | < 10 | n.d. | wt | b3-a2 | no | n.d. |
HNT-34 | M BC | 100 | 10 | n.d. | n.d. | b3-a2 | no | n.d. |
JK-1 | M BC | 100 | 10 | n.d. | n.d. | b2-a2 | no | 1 |
JURL-MK1 | M BC | 200 | < 10 | < 1 | n.d. | b3-a2 | no | n.d. |
JURL-MK2 | M BC | 50 | < 10 | < 1 | n.d. | b3-a2 | no | n.d. |
K-562 | M BC | 200 | 20 | n.d. | n.d. | b3-a2 | no | n.d. |
KCL-22 | M BC | 800 | 40 | 1 | wt | b2-a2 | no | 1.7 |
KU-812 | M BC | 50 | < 10 | n.d. | n.d. | b3-a2 | no | n.d. |
KYO-1 | M BC | 80 | < 10 | < 1 | n.d. | b2-a2 | no | 0.9 |
LAMA-84 | M BC | 100 | < 10 | < 1 | n.d. | b3-a2 | no | n.d. |
MEG-01 | M BC | 200 | < 10 | < 1 | n.d. | b2-a2 | no | n.d. |
MOLM-6 | M BC | 50 | < 10 | < 1 | n.d. | b2-a2 | no | n.d. |
NALM-1 | B BC | > 10000 | 5000 | > 1000 | wt | b2-a2 | no | 1 |
pre B-ALL | Â | Â | Â | Â | Â | Â | Â | Â |
SD-1 | B lymph | > 10000 | 2000 | n.d. | wt | e1-a2 | no | 0.1 |
SUP-B15 | pre B | 2000 | 500 | 100 | wt | e1-a2 | yes | 1.1 |
TOM-1 | pre B | 80 | 5 | n.d. | n.d. | e1-a2 | no | 1 |
T-ALL | Â | Â | Â | Â | Â | Â | Â | Â |
MHH-TALL-1 | T-ALL | 1000 | 1000 | n.d. | wt | e6-a2 | no | n.d. |